Scholarlink

<p>Tovorafenib is a type II RAF inhibitor recently approved by the FDA for relapsed or refractory paediatric low-grade glioma in children aged 6 months and older with BRAF fusions or V600E mutations, owing to its strong central nervous system penetration and absence of paradoxical MAPK pathway activation observed with type I inhibitors. This study developed and validated a fast, robust, and environmentally friendly reversed-phase ultra-performance liquid chromatography method for Tovorafenib quantification, employing ICH Q14 development, ICH Q2(R1) validation, and assimilating Analytical Quality by Design and green analytical chemistry principles. Chromatographic analysis was performed using a Waters Acquity UPLC BEH C18 column and 0.01&#xa0;N Na₂HPO₄ in water: methanol (62:38 v/v) as the mobile phase at 0.29&#xa0;ml/min, with PDA detection at 292&#xa0;nm. The optimized approach exhibited excellent linearity (r² = 0.9997) and reproducibility (low %RSD). Forced degradation studies demonstrated Tovorafenib stability under most conditions, except during acid hydrolysis. Assessment with green chemistry tools yielded favourable eco-scores (ComplexMoGAPI 90, AGREE 0.61, BAGI 70, RAPI 92.5, EVG Q2, and RGBfast 97.5%). This validated RP-UPLC procedure offers reliable, sensitive, and sustainable Tovorafenib analysis, supporting both efficient pharmaceutical quality control and environmental sustainability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Eco-conscious AQbD-guided stability-indicating RP-UPLC method for analysing Tovorafenib in bulk and dosage forms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月5日

查看全文
  • Vanga Mohan Goud,
  • Sarad Pawar Naik Bukke,
  • Praveen Kumar Kusuma,
  • Satla Shobha Rani,
  • M. Sunitha Reddy,
  • Chandrashekar Thalluri,
  • Bayapa Reddy Narapureddy

摘要

Tovorafenib is a type II RAF inhibitor recently approved by the FDA for relapsed or refractory paediatric low-grade glioma in children aged 6 months and older with BRAF fusions or V600E mutations, owing to its strong central nervous system penetration and absence of paradoxical MAPK pathway activation observed with type I inhibitors. This study developed and validated a fast, robust, and environmentally friendly reversed-phase ultra-performance liquid chromatography method for Tovorafenib quantification, employing ICH Q14 development, ICH Q2(R1) validation, and assimilating Analytical Quality by Design and green analytical chemistry principles. Chromatographic analysis was performed using a Waters Acquity UPLC BEH C18 column and 0.01 N Na₂HPO₄ in water: methanol (62:38 v/v) as the mobile phase at 0.29 ml/min, with PDA detection at 292 nm. The optimized approach exhibited excellent linearity (r² = 0.9997) and reproducibility (low %RSD). Forced degradation studies demonstrated Tovorafenib stability under most conditions, except during acid hydrolysis. Assessment with green chemistry tools yielded favourable eco-scores (ComplexMoGAPI 90, AGREE 0.61, BAGI 70, RAPI 92.5, EVG Q2, and RGBfast 97.5%). This validated RP-UPLC procedure offers reliable, sensitive, and sustainable Tovorafenib analysis, supporting both efficient pharmaceutical quality control and environmental sustainability.